We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
201
Nisa Investment Advisors
Missouri
$296K +$22.9K +578 +10%
Royal Bank of Canada
202
Royal Bank of Canada
Ontario, Canada
$286K -$6.78M -170,790 -97%
VEA
203
Virtus ETF Advisers
New York
$272K -$182K -4,580 -44%
HSBC Holdings
204
HSBC Holdings
United Kingdom
$271K -$250K -6,288 -52%
Qube Research & Technologies (QRT)
205
Qube Research & Technologies (QRT)
United Kingdom
$262K -$236K -5,934 -51%
VWM
206
Vigilare Wealth Management
Arizona
$258K -$48.6K -1,225 -18%
EDRH
207
Edmond de Rothschild Holding
Switzerland
$257K -$214K -5,389 -49%
AR
208
Advisory Research
Illinois
$257K +$220K +5,543 New
LPL Financial
209
LPL Financial
California
$254K -$55.7K -1,404 -20%
Commonwealth Equity Services
210
Commonwealth Equity Services
Massachusetts
$252K +$216K +5,445 New
GCP
211
GSA Capital Partners
United Kingdom
$247K +$211K +5,321 New
YIH
212
Y-Intercept (HK)
Hong Kong
$244K +$199K +5,011 New
IRF
213
IBM Retirement Fund
New York
$238K +$203K +5,124 New
CC
214
Centiva Capital
New York
$232K +$199K +5,003 New
XS
215
XR Securities
Illinois
$230K +$197K +4,963 New
BNP Paribas Financial Markets
216
BNP Paribas Financial Markets
France
$229K +$50.3K +1,268 +35%
DCM
217
Dupont Capital Management
Delaware
$226K – – –
Comerica Bank
218
Comerica Bank
Texas
$218K +$182K +4,590 New
JGGDR
219
JGP Global Gestao de Recursos
Brazil
$211K +$180K +4,544 New
DBIA
220
Dumont & Blake Investment Advisors
New Jersey
$211K +$181K +4,550 New
CA
221
Calton & Associates
Florida
$209K +$179K +4,500 New
PCM
222
Prelude Capital Management
New York
$208K -$211K -5,325 -54%
Creative Planning
223
Creative Planning
Kansas
$206K +$176K +4,429 New
WA
224
Wealth Alliance
New York
$204K -$79.4K -2,000 -31%
RG
225
Retirement Group
California
$185K -$1.99K -50 -1%
7 8
9
10 11

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.